Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rhythm Pharmaceuticals, Inc. - Common Stock (NQ:RYTM)

85.53 +1.14 (+1.35%)
Streaming Delayed Price Updated: 1:34 PM EDT, Apr 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 141,802
Open 83.96
Bid (Size) 85.45 (400)
Ask (Size) 85.61 (200)
Prev. Close 84.39
Today's Range 83.96 - 86.89
52wk Range 55.31 - 122.20
Shares Outstanding 66,684,077
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal
In a move that signals a significant consolidation within the rare endocrine disease market, Neurocrine Biosciences (NASDAQ: NBIX) announced on April 6, 2026, that it has entered into a definitive... 
Via MarketMinute

Performance

YTD
-18.6%
-18.6%
1 Month
-2.1%
-2.1%
3 Month
-18.5%
-18.5%
6 Month
-15.1%
-15.1%
1 Year
+42.2%
+42.2%

More News

Read More
News headline image
Soleno Therapeutics: A Masterclass in Rare Disease Redemption and the $2.9B Exit
Via Finterra
Topics Economy Intellectual Property
Rhythm Pharmaceuticals (NASDAQ:RYTM) Posts Q4 Revenue Beat and Narrows Loss ↗
Via Chartmill
RYTM Stock Jumps 4% On Imcivree Revenue Growth: Firm Awaits Approval In Acquired Hypothalamic Obesity By March ↗
Via Stocktwits
News headline image
Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal as VYKAT™ XR Sales Soar
Via MarketMinute
Topics Intellectual Property
News headline image
Rhythm Pharmaceuticals Announces Changes to Board of Directors
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Is This Weight Loss Drug Stock a Buy After a New Approval? ↗
Via The Motley Fool
News headline image
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharma (RYTM) Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position ↗
Via The Motley Fool
News headline image
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Prediction: These 3 Stocks Will Crush the Market in 2026 ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
This High-Flying Growth Stock Is Hiding in Plain Sight ↗
Via The Motley Fool
News headline image
Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Rhythm Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Rhythm Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Rhythm Pharmaceuticals, Inc. - Common Stock trade on?
Rhythm Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Rhythm Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Rhythm Pharmaceuticals, Inc. - Common Stock is RYTM on the Nasdaq Stock Market
What is the current price of Rhythm Pharmaceuticals, Inc. - Common Stock?
The current price of Rhythm Pharmaceuticals, Inc. - Common Stock is 85.53
When was Rhythm Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Rhythm Pharmaceuticals, Inc. - Common Stock was at 04/13/26 01:34 PM ET
What is the market capitalization of Rhythm Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Rhythm Pharmaceuticals, Inc. - Common Stock is 5.70B
How many shares of Rhythm Pharmaceuticals, Inc. - Common Stock are outstanding?
Rhythm Pharmaceuticals, Inc. - Common Stock has 6B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.